These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9220293)

  • 41. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ
    Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
    Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE; Schneider A; Martin DS
    Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
    [No Abstract]   [Full Text] [Related]  

  • 44. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ; Powis G; Rubin J; Moertel CG
    Cancer Treat Rep; 1982 Jan; 66(1):77-80. PubMed ID: 7053270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
    Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
    Martin DS; Kemeny NE
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):49-55. PubMed ID: 1557657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
    Machover D
    Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
    [No Abstract]   [Full Text] [Related]  

  • 48. A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
    Haas NB; Schilder RJ; Nash S; Weiner LM; Catalano RC; Ozols RF; O'Dwyer PJ
    Invest New Drugs; 1995; 13(3):229-33. PubMed ID: 8729951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.
    Garufi C; Lévi F; Aschelter AM; Pace R; Giunta S; Nisticò C; Gallà DA; Silecchia GF; Franchi F; Narduzzi C; Terzoli E
    Eur J Cancer; 1997 Sep; 33(10):1566-71. PubMed ID: 9389916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
    Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
    Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
    Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    de Gramont A; Louvet C; André T; Tournigand C; Krulik M
    Eur J Cancer; 1998 Apr; 34(5):619-26. PubMed ID: 9713264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.
    Martin DS; Kemeny NE
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):228-33. PubMed ID: 1557654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
    Weiss GR; Ervin TJ; Meshad MW; Kufe DW
    Cancer Treat Rep; 1982 Feb; 66(2):299-303. PubMed ID: 7055815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
    Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
    Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
    Petrelli N; Herrera L; Rustum Y; Burke P; Creaven P; Stulc J; Emrich LJ; Mittelman A
    J Clin Oncol; 1987 Oct; 5(10):1559-65. PubMed ID: 2443619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.